Yes. As you mentioned, the gestational trophoblastic disease occurs in the reproductive age group. So most of the patients still need to preserve their fertility. I also will mention about fertility after treatment of cancer. We also have our data in Thailand and also have the data from around the world of little Asia. Overall, the fertility-sparing treatment gives a good outcome for this group of patients, but we have to beware of the long-term toxicity of the chemotherapy like etoposide that may cause secondary cancer in dose accumulation...
Yes. As you mentioned, the gestational trophoblastic disease occurs in the reproductive age group. So most of the patients still need to preserve their fertility. I also will mention about fertility after treatment of cancer. We also have our data in Thailand and also have the data from around the world of little Asia. Overall, the fertility-sparing treatment gives a good outcome for this group of patients, but we have to beware of the long-term toxicity of the chemotherapy like etoposide that may cause secondary cancer in dose accumulation. So the aim of the treatment should be for cure and also preserve fertility sparing in most of the cases. We may have to remove the uterus in some cases, like the very refractory cases for chemotherapy and have the resistant nidus in the uterus in some cases. And let the audience understand the pathophysiology of the disease caused by the abnormal fertilization. And then the genetics of the male can influence the patients to develop the malignant potential.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
